Appendix 4C – Q1 FY25 Quarterly Cash Flow Report [Yahoo! Finance]
Alterity Therapeutics Limited - American Depositary Shares (ATHE)
Company Research
Source: Yahoo! Finance
Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System Atrophy Multiple data presentations at the International Congress of Parkinson's Disease and Movement Disorders ® (MDS) Appointed Abby Macnish Niven as Chief Financial Officer Cash balance on 30 September 2024 of A$9.28m MELBOURNE, Australia and SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2024 (Q1 FY25). “We are excited about what this fiscal year has to offer as we started by reporting promising data from our Phase 2 clinical trial in participants with advanced multiple system atrophy (MSA),” said, David Stamle
Show less
Read more
Impact Snapshot
Event Time:
ATHE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHE alerts
High impacting Alterity Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ATHE
News
- Alterity Therapeutics Appoints Abby Macnish Niven as Company SecretaryGlobeNewswire
- Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium [Yahoo! Finance]Yahoo! Finance
- Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International SymposiumGlobeNewswire
- Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434GlobeNewswire
- Appendix 4C – Q1 FY25 Quarterly Cash Flow ReportGlobeNewswire